Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation is a pioneering biotech company founded in 2009 by Chad Robins and Harlan Robins. The company specializes in harnessing the power of the immune system to transform how diseases are diagnosed and treated. Adaptive uses cutting-edge technologies to decode the genetic language of the adaptive immune system, with applications spanning from diagnostics to therapeutics. This innovative approach has vast potential in various medical fields, especially in cancer and infectious diseases. As of 2023, Chad Robins serves as the CEO, driving the company's vision and growth. Adaptive Biotechnologies is headquartered in Seattle, Washington, and has made significant strides in both its collaborations with industry leaders and its proprietary advances. The company has developed products like the clonoSEQ test, which is utilized for detecting minimal residual disease in certain blood cancers. With a mission to improve patient care and outcomes, Adaptive Biotechnologies continues to be a key player in the biotech industry, attracting attention for its potential to revolutionize healthcare.